The EU has recommended lenacapavir, an injectable drug for HIV prevention, which could drastically reduce transmission rates. With nearly 100% effectiveness, it promises a new era in combating HIV.
The European Medicines Agency has recommended the approval of lenacapavir, a twice-yearly injectable drug that could revolutionize HIV prevention and significantly reduce transmission rates globally.
The WHO's endorsement of lenacapavir, a twice-yearly injectable drug, could transform HIV prevention for high-risk groups, especially amid funding concerns. This breakthrough may help millions and push us closer to an AIDS-free world.
